MétaCan
ENFR
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

Export CSVExport JSONAPI query

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
Topic
Psoriasis: Treatment and Pathogenesis
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

2,393 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
2,393 works in the cohort · of 4,299,418page 34 of 48

Labels cover 8 of 2,393 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 2,393 of 2,393 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

aboutno affunlabeled
A Head-to-Head Comparison of Ixekizumab and Adalimumab in Biologic-Naive Patients with Active Psoriatic Arthritis: Efficacy and Safety Outcomes from a Randomized, Open-Label, Blinded Assessor Study Through 52 Weeks
Josef S Smolen, Peter Nash, Hasan Tahir, Hendrik Schulze‐Koops, Lingnan Li, Maja Hojnik +4 more
2019· article· en· Queensland's institutional digital repository (The University of Queensland)· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
1
citations
affno abstractunlabeled
42664 Itching in patients with moderate to severe plaque psoriasis: The relationship between improvements in Psoriasis Area and Severity Index and patient-reported symptoms in the BE RADIANT phase 3b trial
Matthias Augustin, Richard G. Langley, Richard B. Warren, Mark Lebwohl, Boni E. Elewski, Jeffrey Crowley +4 more
2023· article· en· Journal of the American Academy of Dermatology· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
1
citations
aboutno affunlabeled
Anti‐GM‐CSF therapy in psoriasis
Kim Papp, Melinda Gooderham, Rachel E. Jenkins, Ronald Vender, Jacek C. Szepietowski, T Wagner +2 more
2019· article· en· British Journal of Dermatology· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
1
citations
affvenueunlabeled
Psoriasis
Anatoli Freiman, Benjamin Barankin
2012· article· en· Canadian Medical Association Journal· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
1
citations
aboutno affunlabeled
Drug-related psoriasis
María Ganeva, Tanya Gancheva, Radostina Deliyska, Desislava Gancheva, Evgenya Hristakieva
2023· article· en· Advances in Dermatology and Allergology· Immunology and Microbiology
machine prediction:candidate · insufficient_payloadconsensus · none
1
citations
affno abstractunlabeled
Pityriasis rubra pilaris.
Judith Pitman, Gabrielle Muekusch
2005· article· en· PubMed· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
1
citations
← previousnext →

How this was built: Screen · Findings · About